##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549
 
 FORM 10-K
 þ
    
    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2009
 o
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 FOR THE TRANSITION PERIOD FROM  TO
 
 COMMISSION FILE NUMBER 000-25132
 MYMETICS CORPORATION
  DELAWARE
    
    25-1741849(State or other jurisdiction of
    
    (I.R.S. Employerincorporation or organization)
    
    Identification No.)
 
    
 o þ
 o þ
 þ o
 o o
  o
  Large accelerated filer o
Accelerated filer o
Non-accelerated filer o(Do not check if a smaller reporting company)
Smaller reporting company þ o þ




---



##### Table of Contents



i




---



##### 



PART IITEM 1.
    

BUSINESS
    
    
    4ITEM 1A.
    
    RISK FACTORS
    
    
    13ITEM 2.
    
    PROPERTIES
    
    
    19ITEM 3.
    
    LEGAL PROCEEDINGS
    
    
    19ITEM 4.
    
    SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
    
    
    19PART IIITEM 5.
    
    MARKET FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
    
    
    20ITEM 6.
    
    SELECTED FINANCIAL DATA
    
    
    22ITEM 7.
    
    MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
    
    
    22ITEM 7A.
    
    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
    
    
    28ITEM 8.
    
    FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
    
    
    28ITEM 9.
    
    CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
    
    
    28ITEM 9A.
    
    CONTROLS AND PROCEDURES
    
    
    28ITEM 9B.
    
    OTHER INFORMATION
    
    
    29PART IIIITEM 10.
    
    DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERANCE
    
    
    30ITEM 11.
    
    EXECUTIVE COMPENSATION
    
    
    33ITEM 12.
    
    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
    
    
    37ITEM 13.
    
    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
    
    
    38ITEM 14.
    
    PRINCIPAL ACCOUNTING FEES AND SERVICES
    
    
    38PART IVITEM 15.
    
    EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
    
    
    39SIGNATURES
    
    
    69EX-14.1EX-21.1EX-31.1EX-31.2EX-32.1
  ii




---



##### Table of Contents



MYMETICS S.A.
  4




---



##### Table of Contents



LUXEMBOURG 6543 S.A.
  BESTEWIL HOLDING B.V. and its subsidiary MYMETICS B.V.
    Vaccine
    
    Pre-Clinical
    
    Phase I
    
    Phase IIHIV-1
    
    
    
    XRSV
    
    XHSV
    
    XMalaria
    
    
    
    X
    
    X (ended in 2007)Influenza
    
    
    
    X (finished)
    5




---



##### Table of Contents



Key scientific results with the HIV vaccine to date:
 Proof of Concept for inducing mucosal antibodies
 Mucosal antibodies in monkeys Macaca Mulatta),
 Full protection of monkeys against multiple vaginal challenges with live heterologous
clade B virus SF162P3
 Approval to start Phase I clinical trials
 Production of the GMP-grade vaccine
 Phase I volunteer recruitment and the first
vaccination.
 Next steps:
  Further development of HIV-1 prophylactic vaccine
   6




---



##### Table of Contents



Intranasal Influenza
 Approach:
 Key results to date:
 The vaccine completed pre-clinical trials
 Successful completion of Phase I trial
 Next steps:
   Malaria
 Approach
 Key results to date:
 Mymetics acquired a Malaria vaccine project
 Phase Ib in Tanzania on children and young adults
 Next steps
  
    
    Launching antigen interference study with various combinations
    
    Launching toxicology studies with the best formulation susceptible to offer an improved
protection in human exposed to Plasmodium falciparum.
    
    Launching a new Phase I trial with four or five antigens (peptides and proteins) at the
Swiss Tropical Institute.
 7




---



##### Table of Contents



Respiratory Syncytial Virus (RSV)
 Approach:
 Key Results to date
   Next steps
   Herpes Simplex Virus (HSV)
 Approach
 Key results to date:
  Next steps:
   
    
    Exploiting the results and knowledge of mucosal protection based vaccines
    
    Leveraging the effective and safe virosome vaccine technology and know-how
    
    Advancing existing vaccine candidates only through Phase II clinical trials
    
    Maintaining a comprehensive IP portfolio
    
    Adopting a flexible cost model based on a combination of in-house expertise and
best-in-class outsourcing
    
    Entering into strategic partnerships with leading pharmaceutical companies
 8




---



##### Table of Contents




    
    WO/1999/025377 (GP41 mutée) Method for obtaining vaccines for preventing the
pathogenic effects related to a retroviral infection Mymetics Corp. Expiration
date 16.11.2018
    
    WO/2005/010033 (GP41 ter) New soluble and stabilized trimeric form of GP 41 polypeptide
Mymetics Corp. Expiration date 28.07.2024
    
    WO/2006/117586 (IgA GP41 eng loop) Antibody or a fragment thereof, having neutralizing
activity against HIV but not against IL2 Mymetics Corp + INSERM Expiration date 01.05.2025
    
    WO/2006/117584 (Iga CDR3 long) Antibody or a fragment thereof, having neutralizing
activity against HIV INSERM Expiration date 01.05.2025
    
    WO/2007/099446 (Virosome-P1) Virosome-like vesicles comprising gp41  derived antigens
Mymetics Corp. + INSERM + Pevion Expiration date 01.03.2027
    
    US/61/202 215 (GP41 4th gen) Mymetics Corp. Expiration date 05.02.2029
    
    US/61/202 219 (Splitting GP41) Mymetics Corp. Expiration date 05.02.2029
    
    WO/2004/106366 (UK39) Methods for synthetizing conformationally constrained peptides,
peptidomimetics and use of such peptidomimetics as synthetic vaccines Mymetics Corp.
Expiration date 01.06.2024
    
    WO/2004/078099 (AMA49) Compositions and methods for the generation of immune response
against Malaria Mymetics Corp. Expiration date 02.03.2023
    
    WO/1995/032706 (INEX) Virosome-mediated intracellular delivery of therapeutic agents
Bestewil BV Expiration date 31.05.2015
    
    WO/2004/045641 (APRECS) Antigen-complexes Bestewil BV Expiration date 19.11.2023
    
    WO/2004/110486 (Lipopeptide) Functionally reconstituted viral membranes containing
adjuvant Bestewil BV Expiration date 17.06.2024
    
    WO/2005/117958 (RSV) Vaccine compositions comprising virosomes and a saponin adjuvant
Bestewil BV Expiration date 25.05.2025
    
    WO/2004071492 (DCPC) Virosome-like particles Bestewil BV Expiration date 12.02.2023
 9




---



##### Table of Contents



10




---



##### Table of Contents



11




---



##### Table of Contents



12




---



##### Table of Contents




    
    the timing and cost of product development;
    
    the progress and cost of preclinical and clinical development programs;
    
    the timing and cost of obtaining necessary regulatory approvals;
    
    the timing and cost of sales and marketing activities for future products; and
    
    the costs of pending and any future litigation of which we may be subject.
     13




---



##### Table of Contents




    
    the absence of an operating history;
    
    the lack of commercialized products;
    
    insufficient capital;
    
    expected substantial and continual losses for the foreseeable future;
    
    limited experience in dealing with regulatory issues;
    
    limited marketing experience;
    
    an expected reliance on third parties for the commercialization of our
proposed products;
    
    a competitive environment characterized by numerous, well-established
and well-capitalized competitors;
    
    uncertain market acceptance of our proposed products; and
    
    reliance on key personnel.
   14




---



##### Table of Contents




    
    be successfully developed;
    
    prove to be safe and efficacious in clinical trials;
    
    meet applicable regulatory standards or obtain required regulatory
approvals;
    
    demonstrate substantial protective or therapeutic benefits in the
prevention or treatment of any disease;
    
    be capable of being produced in commercial quantities at reasonable
costs;
    
    obtain coverage and favorable reimbursement rates from insurers and
other third-party payers; or
    
    be successfully marketed or achieve market acceptance by physicians
and patients.
      15




---



##### Table of Contents




    
    slow patient enrollment;
    
    timely completion of clinical site protocol approval and obtaining
informed consent from subjects;
    
    longer trial time than foreseen to demonstrate efficacy or safety;
    
    adverse medical events or side effects in immunized patients; and
    
    lack of effectiveness of the vaccines being tested.
 16




---



##### Table of Contents




    
    the availability of alternative products from competitors;
    
    the price of our products relative to that of our competitors;
    
    the timing of our market entry; and
    
    the ability to market our products effectively.
     
    
    Competitors may interfere with our patents and patent process in a variety of ways.
Competitors may claim that they invented the claimed invention before us or may claim that we are
infringing on their patents and therefore we cannot use our technology as claimed under our patent.
Competitors may also have our patents reexamined by showing the patent examiner that the invention
was not original or novel or was obvious.
    
    We are in the development stage and are in the process of developing proposed products. Even
if we receive a patent, it may not provide much practical protection. If we receive a patent with a
narrow scope, then it will be easier for
competitors to design products that do not infringe on our patent. Even if the development of our
proposed products is successful and approval for sale is obtained, there can be no assurance that
applicable patent coverage, if any, will not have expired or will not expire shortly after this
approval. Any expiration of the applicable patent could have a material adverse effect on the sales
and profitability of our proposed product.
    
    Enforcing patents is expensive and may require significant time by our management. In
litigation, a competitor could claim that our issued patents are not valid for a number of reasons.
If the court agrees, we would lose protection on products covered by those patents.
    
    We also may support and collaborate in research conducted by government organizations or
universities. We cannot guarantee that we will be able to acquire any exclusive rights to
technology or products derived from these collaborations. If we do not obtain required licenses or
rights, we could encounter delays in product development while we attempt to design around other
patents or we may be prohibited from developing, manufacturing or selling products requiring these
licenses. There is also a risk that disputes may arise as to the rights to technology or products
developed in collaboration with other parties.
 17




---



##### Table of Contents




    
    result in costly litigation;
    
    divert the time and attention of our technical personnel and management;
    
    cause product development delays;
    
    require us to develop non-infringing technology; or
    
    require us to enter into royalty or licensing agreements.
    
    
    limit the ability of our stockholders to call special meetings of stockholders;
    
    provide for a staggered board;
    
    provide that our board of directors is expressly authorized to make, alter or
repeal the bylaws; and
    
    establish advance notice requirements for nominations for election to our board
or for proposing matters that can be acted upon by stockholders at stockholder
meetings.
 18




---



##### Table of Contents



19




---



##### Table of Contents



(a)
    
    Market Information. The Corporations common stock is quoted on the OTC Bulletin Board
under the trading symbol MYMX  FISCAL QUARTER ENDED
    
    HIGH
    
    LOW2008March 31
    
    $
    0.250
    
    
    $
    0.250June 30
    
    
    0.210
    
    
    
    0.200September 30
    
    
    0.340
    
    
    
    0.320December 31
    
    
    0.120
    
    
    
    0.1002009March 31
    
    $
    0.190
    
    
    $
    0.170June 30
    
    
    0.189
    
    
    
    0.160September 30
    
    
    0.160
    
    
    
    0.135December 31
    
    
    0.119
    
    
    
    0.110
 
 (b)
    
    Stockholders. At April 15, 2010, we had approximately 600 holders of record of
our common stock, some of which are securities clearing agencies and intermediaries.(c)
    
    Dividends. We have not paid any dividends on our common stock and do not intend
to pay any dividends in the foreseeable future.(d)
    
    Securities Authorized for Issuance under Equity Compensation Plans. 20




---



##### Table of Contents



Number of SecuritiesremainingNumber of Securities to be
    
    
    Weighted Average Exercise
    
    
    available for issuance underissued upon exercise of
    
    
    Price of Outstanding
    
    
    equity compensation plansOptions, Warrants and
    
    
    Options, Warrants and
    
    
    (excluding securitiesRights
    
    
    Rights
    
    
    reflected in column (a))Plan Category
    
    (a)
    
    
    (b)
    
    
    (c)Equity Compensation Plans
Approved by Security
Holders (1)
    
    
    442,500
    (2)
    
    U.S. $
    0.97
    
    
    
    4,557,500Total
    
    
    442,500
    
    
    U.S. $
    0.97
    
    
    
    4,557,500
 
 (1)
    
    Equity compensation plans approved by security holders include (i) the Companys 1994 Amended
and Restated
Stock Option Plan, (ii) its 1995 Qualified Incentive Stock Option Plan and (iii) our 2001 Stock Option Plan.(2)
    
    Includes (i) 442,500 shares of common stock underlying options granted under the registrants
2001 Stock Option Plan.(3)
    
    We do not have any formal equity compensation plan that has not been authorized by our
stockholders.   21




---



##### Table of Contents




    
    On March 13, 2009, a new investor was issued 250,000 common shares of
Mymetics Corporation at $.200 per share, as fee for services rendered.
    
    On May 27, 2009, a previous investor was issued 250,000 common shares of
Mymetics Corporation at $.160 per share, as fee for services rendered.
    
    On September 30, 2009, a previous investor was issued 250,000 common shares of
Mymetics Corporation at $.135 per share, as fee for services rendered.
    
    On February 15, 2010, a new investor was issued 150,000 common shares of
Mymetics Corporation at $.132 per share, as fee for services rendered.
    
    On February 15, 2010, a new investor was issued 50,000 common shares of
Mymetics Corporation at $.132 per share, as fee for services rendered.
 
   
         22




---



##### Table of Contents



23




---



##### Table of Contents



st
        24




---



##### Table of Contents



Dream Vaccines Foundation
             25




---



##### Table of Contents



12 Months2010 budgetGMP lots production & Human Clinical Trials
Phase Ib (HIV)
    
    
    E 4,500,000RSV and HSV
    
    
    2,200,000Further Virosome R&D
    
    
    800,000Administration
    
    
    3,000,000Total
    
    
    E10,500,000
         26




---



##### Table of Contents



27




---



##### Table of Contents



Disclosure Controls and Procedures
  Managements Annual Report on Internal Control over Financial Reporting
     Material Weakness Identified
   28




---



##### Table of Contents



Changes in internal Control over Financial Reporting
  Inherent Limitations on Effectiveness of Controls
   
   29




---



##### Table of Contents



EXPIRATIONOF TERMAS ANAME
    
    CURRENT POSITION WITH THE COMPANY
    
    AGE
    
    DIRECTORJacques-François Martin
(Class II)
    
    Chief Executive Officer, President
and Director (appointed July 1, 2009)
    
    
    65
    
    
    
    2012Ernst Luebke
(Class I)
    
    Chief Financial Officer, Treasurer,
Secretary and Director (appointed July 31, 2003)
    
    
    64
    
    
    
    2010Sylvain Fleury, Ph.D.
(Class III)
    
    Chief Scientific Officer (appointed
November 3, 2003) and Director
(appointed January 11, 2006)
    
    
    46
    
    
    
    2012Christian Rochet
    
    Senior Advisor to the President
    
    
    60
    
    
    2011
    (Class II)Thomas Staehelin
    
    Director
    
    
    62
    
    
    2012
    (Class II)Ernest M. Stern
    
    Director
    
    
    59
    
    
    2010
    (Class I)Marc Girard, DVM, D.Sc.
    
    Consultant to the President
    
    
    74
    
    
    
    n/aRonald Kempers
    
    Chief Operating Officer (appointed July 1st 2009)
    
    
    42
    
    
    
    n/a
       30




---



##### Table of Contents



summa cum laude Law and Policy in International Business
   31




---



##### Table of Contents




    
    Chairman of the Scientific Advisory Board  Dr. Stanley Plotkin, Emeritus
Professor Wistar Institute, University of Pennsylvania, consultant to
Sanofi Pasteur, developed the rubella vaccine in 1960s; worked extensively
on the development and application of other vaccines including polio, rabies,
varicella, rotavirus and cytomegalovirus as well as senior roles at the
Epidemic Intelligence Service, U.S. Public Health Service; Aventis Pasteur
(medical and scientific director); and Sanofi Pasteur (executive advisor).
    
    Vice Chairman of the Scientific Advisory Board  Dr. Marc Girard, has over 20
years of experience in the HIV-1 research field, past Director of the Mérieux
Foundation and a consultant to the WHO and former Chairman of EuroVac
(European Consortium for HIV vaccine).
    
    Dr. Morgane Bomsel, Cochin Institute, France
    
    Dr. Ruth Ruprecht, Harvard University, Dana Farber Cancer Institute,
Boston USA
    
    Dr. Ronald H. Gray, Johns Hopkins University, Baltimore, USA
    
    Dr. Malegapuru William Makgoba, University of KwaZulu-Natal, Durban,
South Africa
    
    Dr. Souleymane Mboup, Cheikh Anta DIOP University, Dakar, Sénégal
    
    Dr. Juliana McElrath, University of Washington, Seattle, USA
    
    Dr. Odile Puijalon, Pasteur Institute, Paris, France
    
    Dr. Caetano Reis e Sousa, Cancer Research UK, London, UK
             32




---



##### Table of Contents



Compensation Philosophy
  (i)
    
    Competitive base salary;(ii)
    
    Granting stock awards as a portion of the total compensation, which
vest over a certain number of years; and(iii)
    
    Granting performance-based bonuses either in cash or common stock.
   33




---



##### Table of Contents



Compensation of Chief Executive Officer
   Compensation of Chief Financial Officer
  Compensation of Chief Scientific Officer
  Compensation of Chief Operating Officer
  34




---



##### Table of Contents



Changes inPension Value andNonqualifiedNon-Equity
    
    
    DeferredStock
    
    
    Option
    
    
    Incentive
    
    
    CompensationSalary
    
    
    Bonus
    
    
    Awards
    
    
    Awards
    
    
    Plan
    
    
    Earnings
    
    
    Compensation
    
    
    All OtherName and Principal Position
    
    
    
    
    
    Year
    
    
    
    (E)
    
    
    (E)
    
    
    E)
    
    
    E)
    
    
    (E)
    
    
    E)
    
    
    (E)
    

    TotalChristian J.-F. Rochet (PEO)
    
    
    (1a
    )
    
    
    2009
    
    
    
    E180,000
    (5)
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    E180,000
    (5)2008
    
    
    
    E216,000
    (5)
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    E216,000
    (5)2007
    
    
    
    E216,000
    (5)
    
    
    
    
    
    
    E807,000
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    E1,023,000
    (5)Jacques-François Martin (PEO)
    
    
    (1b
    )
    
    
    2009
    
    
    
    E120,000
    (5)
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    E120,000
    (5)2008
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    2007
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    Ernst Luebke (PFO)
    
    
    (2
    )
    
    
    2009
    
    
    
    E216,000
    (5)
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    E216,000
    (5)2008
    
    
    
    E216,000
    (5)
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    E216,000
    (5)2007
    
    
    
    E216,000
    (5)
    
    
    
    
    
    
    E672,000
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    E888,000
    (5)Sylvain Fleury, Ph. D.
    
    
    (3
    )
    
    
    2009
    
    
    
    E216,000
    (5)
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    E216,000
    (5)2008
    
    
    
    E216,000
    (5)
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    E216,000
    (5)2007
    
    
    
    E216,000
    (5)
    
    
    
    
    
    
    E672,000
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    E888,000
    (5)Marc Girard, DVM, D.Sc.
    
    
    (4
    )
    
    
    2009
    
    
    
    E48,000
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    E48,000
    (5)2008
    
    
    
    E48,000
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    E48,000
    (5)2007
    
    
    
    E48,000
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    E48,000
    (5)Ronald Kempers
    
    
    (6
    )
    
    
    2009
    
    
    
    E108,000
    (5)
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    E108,000
    (5)2008
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    2007
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
 (1a)
    
    Mr. Rochet has been Mymetics President and Chief Executive Officer from July 31, 2003 to July
1, 2009.(1b)
    
    Mr. Martin has been Mymetics President and Chief Executive Officer from July 1, 2009.(2)
    
    Mr. Luebke has been Mymetics Chief Financial Officer and Treasurer since July 31, 2003 and
our Secretary since August 29, 2003.(3)
    
    Dr. Fleury has been appointed as Mymetics Chief Scientific Officer on November 3, 2003.(4)
    
    Professor Girard has acted as Head of Vaccine Development since January 15, 2004, a position
from which he has resigned for health reasons, as noted above, but he continues to act in an advisory capacity
under a consulting agreement.(5)
    
    See below Employment Agreements.(6)
    
    Mr.Kempers has been Mymetics Chief Operating Officer since July 1, 2009. 35




---



##### Table of Contents



36




---



##### Table of Contents



NAME AND ADDRESS OF
    
    TITLE
    
    AMOUNT AND NATURE OFBENEFICIAL OWNER
    
    OF CLASS
    
    BENEFICIAL OWNERSHIP
    
    PERCENT OF CLASSRound Enterprises Ltd. St. Peter Port, Guernsey
    
    Common
    
    
    44,914,000
    
    
    
    22.88
    %Dr. Thomas Staehelin (1) Director
    
    Common
    
    
    8,500,000
    
    
    
    4.33
    %Ernst Luebke (1) 
Chief Financial Officer, Secretary and Director
    
    Common
    
    
    8,829,546
    (2)
    
    
    4.50
    %Christian Rochet (1) 
Former Chief Executive Officer, and Director
    
    Common
    
    
    6,709,733
    (3)
    
    
    3.42
    %Dr. Sylvain Fleury (1)
Chief Scientific Officer, and Director
    
    Common
    
    
    6,500,000
    (4)
    
    
    3.31
    %Jacques-François Martin (1) 
Chief Executive Officer, President and Director
    
    Common
    
    
    1,430,307
    
    
    
    0.73
    %Mr. Ernest M. Stern (1) Director and outside Counsel
    
    Common
    
    
    1,500,000
    
    
    
    0.76
    %Prof. Marc Girard (1)Consultant and member of the SAB
    
    Common
    
    
    500,000
    (5)
    
    
    0.25
    %Prof. Morgane Bomsel (1)Consultant and member of the SAB
    
    Common
    
    
    500,000
    (6)
    
    
    0.25
    %All current executive officers and
directors as a group (6 persons)
    
    Common
    
    
    33,269,586
    
    
    
    16.95
    %
 
 (1)
    
    Address is Mymetics Corporation, c/o Mymetics S.A., Biopole,
Route de la Corniche 4, CH-1066 Epalinges (Switzerland).(2)
    
    Of which 2,829,546 acquired prior to being elected as director and appointed
as officer, 1,000,000 acquired through conversion of unpaid salary and
expenses and 5,000,000 acquired as bonus.(3)
    
    Of which 1627009 acquired prior to being elected as director and appointed
as officer, 1,000,000 acquired through conversion of unpaid salary and
expenses and 6,000,000 acquired as bonus.(4)
    
    Of which 500,000 issued for services, 1,000,000 acquired through conversion
of unpaid salary and expenses and 5,000,000 acquired as bonus.(5)
    
    Of which 500,000 issued for services and 500,000 acquired through conversion
of unpaid fees and expenses. 500,000 have been sold in 2006.(6)
    
    500,000 issued for services rendered. 37




---



##### Table of Contents



2009
    
    
    2008Audit Fees
    
    $
    72,000
    
    
    $
    57,000Audit-Related Fees
    
    
    
    
    
    
    Tax Fees
    
    
    9,500
    
    
    
    41,000All Other Fees
    
    
    
    
    
    
    Total
    
    $
    81,500
    
    
    $
    98,000
       38




---



##### Table of Contents



(a)(1)
    
    Index to Financial StatementsReport of Independent Registered Public Accounting FirmConsolidated Balance SheetsConsolidated Statements of Operations and Comprehensive LossConsolidated Statements of Changes in Shareholders Equity (Deficit)Consolidated Statements of Cash FlowsNotes to Consolidated Financial Statements(a)(2)
    
    ALL OTHER SCHEDULES HAVE BEEN OMITTED BECAUSE THEY ARE NOT APPLICABLE OR THE
REQUIRED INFORMATION IS SHOWN IN THE FINANCIAL STATEMENTS OR NOTES THERETO.(3)
    
    List of Exhibits2.1
    
    Share Exchange Agreement dated December 13, 2001 between the Corporation and
the stockholders of Mymetics S.A. listed on the signature page thereto (1)2.2
    
    Share Exchange Agreement dated December 13, 2001 between the Company and the
stockholders of Mymetics S.A. listed on the signature page thereto (1)2.3
    
    Purchase Agreement dated October 17, 1998 between the Company and the
majority stockholders of Nazca Holdings Ltd. (2)2.4
    
    Amendment to the Purchase Agreement dated October 17, 1998 between the
Company and the majority stockholders of Nazca Holdings Ltd. (3)2.5
    
    Revised Purchase Agreement dated July 28, 1999 between the Company and the
majority stockholders of Nazca Holdings Ltd. (4)2.6
    
    Share Exchange Agreement dated July 30, 2002 between the Company and the
stockholders of Mymetics S.A. listed on the signature page thereto (5)3(i)
    
    Articles of Incorporation of the Company (as amended through May 10, 2002) (6)3(ii)
    
    Bylaws (7)4.1
    
    Form of Specimen Stock Certificate (8)4.2
    
    Form of letter regarding Warrant (8)4.3
    
    Form of Share Exchange Agreement (8)9.1
    
    Voting and Exchange Trust Agreement dated March 19, 2001, among the Company,
6543 Luxembourg S.A. and MFC Merchant Bank S.A. (8)
 39




---



##### Table of Contents



10.1
    
    Services Agreement dated May 31, 2001, between the Company and MFC Merchant Bank, S.A.(7)10.2
    
    Employment Agreement dated May 3, 2001, between Pierre-Francois Serres and the Company (7)10.3
    
    Indemnification Agreement dated March 19, 2001, between the Company and MFC Bancorp Ltd. (7)10.4
    
    Agreement dated for reference May 15, 2000, between the Company and Maarten Reidel (7)10.5
    
    Preferred Stock Redemption and Conversion Agreement dated for reference December 21, 2000,
between the Company and Sutton Park International Ltd. (10)10.6
    
    Preferred Stock Conversion Agreement dated for reference December 21, 2000, between the Company
and Med Net International Ltd. (11)10.7
    
    Preferred Stock Conversion Agreement dated December 21, 2000, between the Company and Dresden
Papier GmbH (11)10.8
    
    Assignment Agreement dated December 29, 2000, among the Company, Mymetics S.A. and MFC Merchant
Bank S.A. (1)10.9
    
    Credit Facility Agreement dated July 27, 2000, between MFC Merchant Bank, S.A. and the Company (1)10.10
    
    Amended Credit Facility Agreement dated for reference August 13, 2001, between MFC Merchant Bank,
S.A. and the Company (16)10.11
    
    Second Amended Credit Facility Agreement dated for reference February 27, 2002, between MFC
Merchant Bank, S.A. and the Company (16)10.12
    
    Amended and Restated Credit Facility Agreement dated for reference February 28, 2003, among MFC
Merchant Bank, S.A., MFC Bancorp Ltd., and the Company (16)10.13
    
    Guarantee dated for reference February 28, 2003, by MFC Bancorp Ltd. to MFC Merchant Bank S.A. (16)10.14
    
    Shareholder Agreement dated March 19, 2001, among the Company, the Holders of Class B Exchangeable
Preferential Non-Voting Shares of 6543 Luxembourg S.A. signatory thereto and 6543 Luxembourg
S.A.(8)10.15
    
    Support Agreement dated March 19, 2001, between the Company and 6543 Luxembourg S.A. (8)
 40




---



##### Table of Contents



10.16
    
    1995 Qualified Incentive Stock Option Plan (12)10.17
    
    Amended 1994 Stock Option Plan (13)10.18
    
    2001 ICHOR Company Stock Option Plan (7)10.19
    
    Employment Agreement dated March 18, 2002, between the
Company and Peter P. McCann (14)10.20
    
    Consulting Agreement dated August 31, 2001, between the
Company and Michael K. Allio (8)10.21
    
    Amendment to Consulting Agreement dated August 21, 2002,
between the Company and Michael K. Allio (16)10.22
    
    Employment Agreement dated March 18, 2002, between the Company and Dr. Joseph D. Mosca (15)10.23
    
    Separation Agreement and Release dated January 31, 2003, between the Company and Peter P. McCann (16)10.24
    
    Director and Non-Employee Stock Option Agreement dated July 19, 2001, between the Company and Robert
Demers (8)10.25
    
    Director and Non-Employee Stock Option Agreement dated July 19, 2001, between the Company and
Michael K. Allio (8)10.26
    
    Director and Non-Employee Stock Option Agreement dated July 19, 2001, between the Company and John
M. Musacchio (8)10.27
    
    Director and Non-Employee Stock Option Agreement dated July 19, 2001, between the Company and
Patrice Pactol (8)10.28
    
    Director and Non-Employee Stock Option Agreement dated July 19, 2001, between the Company and
Pierre-Francois Serres (8)10.29
    
    Director and Non-Employee Stock Option Agreement dated July 23, 2002, between the Company and
Pierre-Francois Serres (16)10.30
    
    Director and Non-Employee Stock Option Agreement dated July 23, 2002, between the Company and
Patrice Pactol (16)10.31
    
    Director and Non-Employee Stock Option Agreement dated July 23, 2002, between the Company and Robert
Demers (16)10.32
    
    Director and Non-Employee Stock Option Agreement dated July 23, 2002, between the Company and John
M. Musacchio (16)10.33
    
    Director and Non-Employee Stock Option Agreement dated July 23, 2002, between the Company and
Michael K. Allio (16)10.34
    
    Director and Non-Employee Stock Option Agreement dated August21, 2002, between the Company and
Michael K. Allio (16)10.35
    
    Director and Non-Employee Stock Option Agreement dated June 20, 2002, between the Company and Peter
P. McCann (16)10.36
    
    Director and Non-Employee Stock Option Agreement dated July 23, 2002, between the Company and Peter
P. McCann (16)10.37
    
    Director and Non-Employee Stock Option Agreement dated February 6, 2003, between the Company and
Peter P. McCann (16)10.38
    
    Patent Pledge Agreement dated November __, 2002 among Mymetics S.A., Mymetics Deutschland GmbH, the
Company and MFC Merchant Bank S.A. (16)10.39
    
    Third Amendment to the Credit Facility Agreement dated for Reference December 31, 2006, between MFC
Merchant Bank, S.A. and the Company (17)10.40
    
    Fourth Amendment to the Credit Facility Agreement dated for Reference February 16, 2005, between MFC
Merchant Bank, S.A. and the Company (17)
 41




---



##### Table of Contents



10.41
    
    Consulting Agreement dated for reference January 1, 2004, between the Centre
Hospitalier Universitaire Vaudois (CHUV), the Company and Dr. Sylvain Fleury,
Ph.D. (18)10.42
    
    Consulting Agreement dated for reference January 1, 2004, between the Company and
Professor Marc Girard, DVM, D.Sc. (18)10.43
    
    Cooperation and Option Agreement dated March 10, 2005, between the Company and
Pevion A.G. (18)10.44
    
    Consulting Agreement dated March 23, 2005, between the Company and Northern Light
International. (18)10.45
    
    Sixth Amended Credit Facility Agreement dated for reference December 31, 2005,
between MFC Merchant Bank, S.A. and the Company (19)10.46
    
    Employment Agreement dated July 1, 2006, between the Company and Dr. Sylvain
Fleury (20)10.47
    
    Employment Agreement dated July 1, 2006, between the Company and Christian Rochet
(20)10.48
    
    Employment Agreement dated July 1, 2006, between the Company and Ernst Luebke (20)10.49
    
    License Agreement dated March 1, 2007, between the Company and Pevion Biotech
Ltd. (21)10.50
    
    Settlement Agreement dated March 19, 2007 between Mymetics and MFC Merchant Bank
S.A. (22)10.51
    
    Co-ownership Agreement dated January 8, 2008 between the Company, INSERM and
Pevion Biotech Ltd. (23)10.52
    
    Co-ownership Agreement dated January 8, 2008 between the Company and INSERM (23)10.53
    
    Exploitation Agreement dated January 8, 2008 between the Company and INSERM (23)10.54
    
    Non-Executive Director Agreement dated 21 January between the Company and Mr
Ernest M Stern.(24)10.55
    
    NGIN Material Transfer Agreement dated 11 February 2008 between the Company,
Institute Cochin, Université Paris Descartes and Pevion Biotech.(25)
 42




---



##### Table of Contents



10.56
    
    Acquisition & License Agreement dated 19 May 2008 between the Company and
Pevion Biotech Ltd. (26)10.57
    
    Extension of Convertible Note Maturity Date Agreement dated 22 August 2008
between the Company, Anglo Irish Bank and Round Enterprises Ltd. (27)10.58
    
    Gp41 Manufacturing Technology Agreement dated 26 January 2009 between the
Company and PX Therapeutics (28)10.59
    
    Share Purchase Agreement pursuant to which Mymetics purchased all issued and
outstanding shares of capital stock of Bestewil Holding B.V. (Bestewil) from
its parent, Norwood Immunology Limited(NIL), and all issued and outstanding
shares of capital stock of Virosome Biologicals B.V. now held by Bestewil. (29)10.60
    
    Resignation of Prof Marc Girard as Head of vaccine development for reasons of
personal health. (30)10.61
    
    Completion of Share Purchase Agreement pursuant to which Mymetics purchased all
issued and outstanding shares of capital stock of Bestewil Holding B.V. and
Virosome Biologicals B.V. including Unregistered Sales of Equity Securities,
Financial Statements and Exhibits. (31)10.62
    
    Completion of Share Purchase Agreement pursuant to which Mymetics purchased all
issued and outstanding shares of capital stock of Bestewil Holding B.V. and
Virosome Biologicals B.V. including Unregistered Sales of equity Securities,
further Financial Statements and Exhibits. (32)10.63
    
    Election of Jacques-François Martin as a member of the Board of Directors and
Chairman of the Board, resignation of Christian Rochet as President and CEO and
agreement of Jacques-François Martin to serve as President and CEO. (33)11.1
    
    Statement Regarding Calculation of Per Share Earnings.14.1
    
    Code of Ethics.21.1
    
    List of Subsidiaries24.1
    
    Powers of Attorney (included on the signature page hereto)31.1
    
    Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14 of
the Securities Exchange Act of 193431.2
    
    Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14 of
the Securities Exchange Act of 193432.1
    
    Section 1350 Certification of Chief Executive Officer and Chief Financial Officer
 43




---



##### Table of Contents



(1)
    
    Incorporated by reference to the Companys Schedule 14C filed with
the Securities and Exchange Commission on April 26, 2001.(2)
    
    Incorporated by reference to the Companys report on Form 8-K filed
with the Securities and Exchange Commission on October 22, 1998.(3)
    
    Incorporated by reference to the Companys report on Form 8-K/A filed
with the Securities and Exchange Commission on April 15, 1999.(4)
    
    Incorporated by reference to the Companys report on Form 8-K/A filed
with the Securities and Exchange Commission on August 13, 1999.(5)
    
    Incorporated by reference to the Companys Amendment No. 1 to Form
S-1 filed with the Securities and Exchange Commission on August 8,
2002.(6)
    
    Incorporated by reference to the Companys report on Form 10-Q for
the quarter ended March 31, 2002, filed with the Securities and
Exchange Commission on May 15, 2002.(7)
    
    Incorporated by reference to the Companys report on Form 10-Q for
the quarter ended June 30, 2001, filed with the Securities and
Exchange Commission on August 14, 2001.(8)
    
    Incorporated by reference to the Companys Registration Statement on
Form S-1, File No. 333-88782, filed with the Securities and Exchange
Commission on May 22, 2002.(9)
    
    Incorporated by reference to the Companys report on Form 8-K/A filed
with the Securities and Exchange Commission on August 9, 2000.(10)
    
    Incorporated by reference to Schedule 13D/A filed by MFC Bancorp Ltd.
with the Securities and Exchange Commission on dated January 2, 2001.(11)
    
    Incorporated by reference to the Companys report on Form 10-K for
the fiscal year ended December 31, 2000, filed with the Securities
and Exchange Commission on March 14, 2001.(12)
    
    Incorporate by reference to the Companys Registration Statement on
Form S-8, File No. 333-15831, filed with the Securities and Exchange
Commission on November 8, 1996.(13)
    
    Incorporated by reference to the Companys Registration Statement on
Form S-8, File No. 333-15829, filed with the Securities and Exchange
Commission on November 8, 1996.(14)
    
    Incorporated by reference to the Companys report on Form 10-K for
the fiscal year ended December 31, 2004, and filed with the
Securities and Exchange Commission on March 29, 2002.(15)
    
    Incorporated by reference to the Companys report on Form 10-Q for
the quarter ended March 31, 2002, filed with the Securities and
Exchange Commission on May 15, 2002.(16)
    
    Incorporated by reference to the Companys report on Form 10-K for
the fiscal year ended December 31, 2005, and filed with the
Securities and Exchange Commission on March 27, 2003.(17)
    
    Incorporated by reference to the Companys report on Form 8-K filed
with the Securities and Exchange Commission on February 18, 2005.(18)
    
    Incorporated by reference to the Companys report on Form 10-K for
the fiscal year ended December 31, 2004, filed with the Securities
and Exchange Commission on March 30, 2005.(19)
    
    Incorporated by reference to the Companys report on Form 10-K for
the fiscal year ended December 31, 2005, filed with the Securities
and Exchange Commission on April 17, 2006.(20)
    
    Incorporated by reference to the Companys report on Form 10-Q for
the period ended June 30, 2006, and filed with the Securities and
Exchange Commission on August 21, 2006.(21)
    
    Incorporated by reference to the Companys report on Form 10-K for
the fiscal year ended December 31, 2006, filed with the Securities
and Exchange Commission on April 17, 2007. 44




---



##### Table of Contents



(22)
    
    Incorporated by reference to the Companys report on Form 8-K filed
with the Securities and Exchange Commission on March 21, 2007.(23)
    
    Incorporated by reference to the Companys report on Form 8-K filed
with the Securities and Exchange Commission on January 14, 2008.(24)
    
    Incorporated by reference to the Companys report on Form 8-K filed
with the Securities and Exchange Commission on January 25, 2008.(25)
    
    Incorporated by reference to the Companys report on Form 8-K filed
with the Securities and Exchange Commission on February 19, 2008.(26)
    
    Incorporated by reference to the Companys report on Form 8-K filed
with the Securities and Exchange Commission on May 19, 2008.(27)
    
    Incorporated by reference to the Companys report on Form 8-K filed
with the Securities and Exchange Commission on June 30, 2008.(28)
    
    Incorporated by reference to the Companys report on Form 8-K filed
with the Securities and Exchange Commission on January 30, 2009.(29)
    
    Incorporated by reference to the Companys report on Form 8-K filed
with the Securities and Exchange Commission on March 5, 2009.(30)
    
    Incorporated by reference to the Companys report on Form 8-K filed
with the Securities and Exchange Commission on March 9, 2009.(31)
    
    Incorporated by reference to the Companys report on Form 8-K filed
with the Securities and Exchange Commission on June 16, 2009.(32)
    
    Incorporated by reference to the Companys report on Form 8-K/A filed
with the Securities and Exchange Commission on June 22, 2009.(33)
    
    Incorporated by reference to the Companys report on Form 8-K filed
with the Securities and Exchange Commission on June 23, 2009.(c)
    
    Financial Statements 45




---



##### Table of Contents



46




---



##### Table of Contents



2009
    
    
    2008ASSETSCurrent AssetsCash
    
    E
    2,959
    
    
    E
    509Receivables officer
    
    
    6
    
    
    
    8Receivables other
    
    
    39
    
    
    
    6Prepaid expenses
    
    
    34
    
    
    
    75Total current assets
    
    
    3,038
    
    
    
    598Property and equipment, net of accumulated
depreciation of E100 and E18 at December 31,
2009 and 2008, respectively
    
    
    232
    
    
    
    76License contract, net of accumulated
amortization of E144 at December 31, 2009
and Nil at December 31, 2008
    
    
    2,550
    
    
    
    In-process research and development
    
    
    2,266
    
    
    
    Goodwill
    
    
    6,671
    
    
    
    E
    14,757
    
    
    E
    674LIABILITIES AND SHAREHOLDERS EQUITY (DEFICIT)Current LiabilitiesAccounts payable
    
    E
    1,540
    
    
    E
    991Taxes and social costs payable
    
    
    41
    
    
    
    25Current portion of convertible notes payable
to related parties
    
    
    5,740
    
    
    
    Total current liabilities
    
    
    7,321
    
    
    
    1,016Convertible notes payable to related parties,
less current portion
    
    
    21,722
    
    
    
    8,973Convertible notes payable, other
    
    
    2,593
    
    
    
    Acquisition-related contingent consideration
    
    
    1,936
    
    
    
    Total liabilities
    
    
    33,572
    
    
    
    9,989Shareholders Equity (Deficit)Common stock, U.S. $.01 par value;
495,000,000 shares authorized; issued 196,063,630
at December 31, 2009 and 194,313,630 at December 31, 2008
    
    
    1,754
    
    
    
    1,742Common stock issuable, nil at December 31, 2009 and
1,000,000 at December 31, 2008
    
    
    
    
    
    
    7Preferred stock, U.S. $.01 par value;
5,000,000 shares authorized; none issued or outstanding
    
    
    
    
    
    
    Additional paid-in capital
    
    
    20,840
    
    
    
    20.155Deficit accumulated during the development stage
    
    
    (42,090
    )
    
    
    (31,904
    )Accumulated other comprehensive income
    
    
    681
    
    
    
    685(18,815
    )
    
    
    (9,315
    )E
    14,757
    
    
    E
    674
  47




---



##### Table of Contents



AccumulatedDuringDevelopmentStage(May 2, 1990 toDecember 31,2009
    
    
    2008
    
    
    2009)RevenuesSales
    
    E
    136
    
    
    E
    
    
    
    E
    360Interest
    
    
    1
    
    
    
    
    
    
    
    35Gain on extinguishment of debt
    
    
    
    
    
    
    
    
    
    
    774Government grants
    
    
    13
    
    
    
    65
    
    
    
    78150
    
    
    
    65
    
    
    
    1,247ExpensesResearch and development
    
    
    6,364
    
    
    
    2,692
    
    
    
    20,666General and administrative
    
    
    3,244
    
    
    
    3,693
    
    
    
    18,005Bank fee
    
    
    2
    
    
    
    
    
    
    
    937Interest
    
    
    2,082
    
    
    
    583
    
    
    
    4,034Change in the fair value of
acquisition-related
contingent consideration
    
    
    (1,614
    )
    
    
    
    
    
    
    (1,614
    )Goodwill impairment
    
    
    
    
    
    
    
    
    
    
    209Depreciation and amortization
    
    
    226
    
    
    
    17
    
    
    
    756Directors fees
    
    
    42
    
    
    
    
    
    
    
    316Other
    
    
    
    
    
    
    
    
    
    
    1010,346
    
    
    
    6,985
    
    
    
    43,319Loss before income taxes
    
    
    (10,196
    )
    
    
    (6,920
    )
    
    
    (42,072
    )Income tax (provision) benefit
    
    
    10
    
    
    
    (18
    )
    
    
    (18
    )Net loss
    
    
    (10,186
    )
    
    
    (6,938
    )
    
    
    (42,090
    )Other comprehensive income (loss)Foreign currency translation
adjustment
    
    
    (4
    )
    
    
    13
    
    
    
    681Comprehensive loss
    
    E
    (10,190
    )
    
    E
    (6,925
    )
    
    E
    (41,409
    )Basic and diluted loss per share
    
    E
    (0.05
    )
    
    E
    (0.04
    )
  48




---



##### Table of Contents



AccumulatedOtherDeficit
    
    
    ComprehensiveAccumulated
    
    
    Income - ForeignAdditional
    
    
    During the
    
    
    CurrencyDate of
    
    
    Number of
    
    
    Par
    
    
    Paid-in
    
    
    Development
    
    
    TranslationTransaction
    
    
    Shares
    
    
    Value
    
    
    Capital
    
    
    Stage
    
    
    Adjustment
    
    
    TotalBalance at May 2, 1990Shares issued for cash
    
    June 1990
    
    
    
    33,311,361
    
    
    E
    119
    
    
    E
    
    
    
    E
    
    
    
    E
    
    
    
    E
    119Net losses to December 31, 1999
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (376
    )
    
    
    
    
    
    
    (376
    )Balance at December 31, 1999
    
    
    
    
    
    
    33,311,361
    
    
    
    119
    
    
    
    
    
    
    
    (376
    )
    
    
    
    
    
    
    (257
    )Bank fee
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    806
    
    
    
    
    
    
    
    
    
    
    
    806Net loss for the year
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (1,314
    )
    
    
    
    
    
    
    (1,314
    )Balance at December 31, 2000
    
    
    
    
    
    
    33,311,361
    
    
    
    119
    
    
    
    806
    
    
    
    (1,690
    )
    
    
    
    
    
    
    (765
    )Effect on capital structure resulting
from a business combination
    
    March 2001
    
    
    8,165,830
    
    
    
    354
    
    
    
    (354
    )
    
    
    
    
    
    
    
    
    
    
    Issuance of stock purchase warrants in
connection with credit facility
(restated)
    
    March 2001
    
    
    
    
    
    
    
    
    
    
    
    210
    
    
    
    
    
    
    
    
    
    
    
    210Issuance of shares for bank fee
    
    March 2001
    
    
    
    1,800,000
    
    
    
    21
    
    
    
    (21
    )
    
    
    
    
    
    
    
    
    
    
    Issuance of shares for bank fee
    
    June 2001
    
    
    
    225,144
    
    
    
    3
    
    
    
    (3
    )
    
    
    
    
    
    
    
    
    
    
    Issuance of shares for cash
    
    June 2001
    
    
    
    1,333,333
    
    
    
    15
    
    
    
    2,109
    
    
    
    
    
    
    
    
    
    
    
    2,124Exercise of stock purchase warrants in
repayment of debt
    
    June 2001
    
    
    
    1,176,294
    
    
    
    13
    
    
    
    259
    
    
    
    
    
    
    
    
    
    
    
    272Exercise of stock purchase warrants
for cash
    
    December 2001
    
    
    
    3,250,000
    
    
    
    37
    
    
    
    563
    
    
    
    
    
    
    
    
    
    
    
    600Net loss for the year (restated)
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (1,848
    )
    
    
    
    
    
    
    (1,848
    )Translation adjustment
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    100
    
    
    
    100Balance at December 31, 2001
    
    
    
    
    
    
    49,261,962
    
    
    
    562
    
    
    
    3,569
    
    
    
    (3,538
    )
    
    
    100
    
    
    
    693Exercise of stock options
    
    March 2002
    
    
    
    10,000
    
    
    
    
    
    
    
    8
    
    
    
    
    
    
    
    
    
    
    
    8Issuance of stock purchase warrants
for bank fee
    
    June 2002
    
    
    
    
    
    
    
    
    
    
    
    63
    
    
    
    
    
    
    
    
    
    
    
    63Exercise of stock purchase warrants in
repayment of debt
    
    July 2002
    
    
    
    1,625,567
    
    
    
    16
    
    
    
    396
    
    
    
    
    
    
    
    
    
    
    
    412Issuance of remaining shares from 2001
business combination
    
    August 2002
    
    
    
    46,976
    
    
    
    1
    
    
    
    (1
    )
    
    
    
    
    
    
    
    
    
    
    Net loss for the year
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (3,622
    )
    
    
    
    
    
    
    (3,622
    )Translation adjustment
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    97
    
    
    
    97Balance at December 31, 2002
    
    
    
    
    
    
    50,944,505
    
    
    
    579
    
    
    
    4,035
    
    
    
    (7,160
    )
    
    
    197
    
    
    
    (2,349
    )
 49




---



##### Table of Contents



AccumulatedOtherDeficit
    
    
    ComprehensiveAccumulated
    
    
    Income - ForeignAdditional
    
    
    During the
    
    
    CurrencyDate of
    
    
    Number of
    
    
    Par
    
    
    Paid-in
    
    
    Development
    
    
    TranslationTransaction
    
    
    Shares
    
    
    Value
    
    
    Capital
    
    
    Stage
    
    
    Adjustment
    
    
    TotalIssuance of shares for services
    
    September 2003
    
    
    
    400,000
    
    
    
    4
    
    
    
    29
    
    
    
    
    
    
    
    
    
    
    
    33Shares retired
    
    October 2003
    
    
    
    (51
    )
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    Issuance of shares for services
    
    November 2003
    
    
    
    1,500,000
    
    
    
    12
    
    
    
    100
    
    
    
    
    
    
    
    
    
    
    
    112Issuance of shares for cash
    
    December 2003
    
    
    
    1,500,000
    
    
    
    12
    
    
    
    113
    
    
    
    
    
    
    
    
    
    
    
    125Issuance of stock purchase warrants
for financing fee
    
    December 2003
    
    
    
    
    
    
    
    
    
    
    
    12
    
    
    
    
    
    
    
    
    
    
    
    12Net loss for the year
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (2,786
    )
    
    
    
    
    
    
    (2,786
    )Translation adjustment
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    453
    
    
    
    453Balance at December 31, 2003
    
    
    
    
    
    
    54,344,454
    
    
    
    607
    
    
    
    4,289
    
    
    
    (9,946
    )
    
    
    650
    
    
    
    (4,400
    )
 50




---



##### Table of Contents



AccumulatedOtherDeficit
    
    
    ComprehensiveAccumulated
    
    
    Income  ForeignAdditional
    
    
    During the
    
    
    CurrencyDate of
    
    
    Number of
    
    
    Par
    
    
    Paid-in
    
    
    Development
    
    
    TranslationTransaction
    
    
    Shares
    
    
    Value
    
    
    Capital
    
    
    Stage
    
    
    Adjustment
    
    
    TotalIssuance of shares for services
    
    January 2004
    
    
    
    550,000
    
    
    
    5
    
    
    
    27
    
    
    
    
    
    
    
    
    
    
    
    32Issuance of shares for cash
    
    January 2004
    
    
    
    2,000,000
    
    
    
    17
    
    
    
    150
    
    
    
    
    
    
    
    
    
    
    
    167Issuance of stock purchase warrants
for financing fee
    
    January 2004
    
    
    
    
    
    
    
    
    
    
    
    40
    
    
    
    
    
    
    
    
    
    
    
    40Issuance of shares for cash
    
    February 2004
    
    
    
    2,500,000
    
    
    
    21
    
    
    
    187
    
    
    
    
    
    
    
    
    
    
    
    208Issuance of stock purchase warrants
for financing fee
    
    February 2004
    
    
    
    
    
    
    
    
    
    
    
    62
    
    
    
    
    
    
    
    
    
    
    
    62Issuance of shares for services
    
    April 2004
    
    
    
    120,000
    
    
    
    1
    
    
    
    11
    
    
    
    
    
    
    
    
    
    
    
    12Issuance of shares for bank fee
    
    May 2004
    
    
    
    500,000
    
    
    
    4
    
    
    
    62
    
    
    
    
    
    
    
    
    
    
    
    66Issuance of shares for cash
    
    May 2004
    
    
    
    2,000,000
    
    
    
    16
    
    
    
    148
    
    
    
    
    
    
    
    
    
    
    
    164Issuance of shares for services
    
    August 2004
    
    
    
    250,000
    
    
    
    2
    
    
    
    26
    
    
    
    
    
    
    
    
    
    
    
    28Issuance of shares for cash
    
    August 2004
    
    
    
    1,466,667
    
    
    
    12
    
    
    
    128
    
    
    
    
    
    
    
    
    
    
    
    140Issuance of stock purchase warrants
for financing fee
    
    August 2004
    
    
    
    
    
    
    
    
    
    
    
    46
    
    
    
    
    
    
    
    
    
    
    
    46Issuance of shares for services
    
    September 2004
    
    
    
    520,000
    
    
    
    4
    
    
    
    29
    
    
    
    
    
    
    
    
    
    
    
    33Issuance of shares for cash
    
    September 2004
    
    
    
    50,000
    
    
    
    
    
    
    
    4
    
    
    
    
    
    
    
    
    
    
    
    4Issuance of shares for services
    
    October 2004
    
    
    
    2,106,743
    
    
    
    16
    
    
    
    132
    
    
    
    
    
    
    
    
    
    
    
    148Issuance of shares for services
    
    November 2004
    
    
    
    2,000,000
    
    
    
    15
    
    
    
    177
    
    
    
    
    
    
    
    
    
    
    
    192Issuance of shares for cash
    
    November 2004
    
    
    
    40,000
    
    
    
    
    
    
    
    4
    
    
    
    
    
    
    
    
    
    
    
    4Net loss for the year
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (2,202
    )
    
    
    
    
    
    
    (2,202
    )Translation adjustment
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    191
    
    
    
    191Balance at December 31, 2004
    
    
    
    
    
    
    68,447,864
    
    
    E
    720
    
    
    E
    5,522
    
    
    E
    (12,148
    )
    
    E
    841
    
    
    E
    (5,065
    )
 51




---



##### Table of Contents



AccumulatedOtherDeficit
    
    
    ComprehensiveAccumulated
    
    
    Income  ForeignAdditional
    
    
    During the
    
    
    CurrencyDate of
    
    
    Number of
    
    
    Par
    
    
    Paid-in
    
    
    Development
    
    
    TranslationTransaction
    
    
    Shares
    
    
    Value
    
    
    Capital
    
    
    Stage
    
    
    Adjustment
    
    
    TotalIssuance of shares for services
    
    January 2005
    
    
    
    500,000
    
    
    
    4
    
    
    
    83
    
    
    
    
    
    
    
    
    
    
    
    87Issuance of shares for services
    
    March 2005
    
    
    
    200,000
    
    
    
    2
    
    
    
    33
    
    
    
    
    
    
    
    
    
    
    
    35Issuance of shares for services
    
    March 2005
    
    
    
    1,500,000
    
    
    
    11
    
    
    
    247
    
    
    
    
    
    
    
    
    
    
    
    258Issuance of shares for services
    
    April 2005
    
    
    
    60,000
    
    
    
    1
    
    
    
    10
    
    
    
    
    
    
    
    
    
    
    
    11Issuance of shares for cash
    
    May 2005
    
    
    
    52,000
    
    
    
    
    
    
    
    5
    
    
    
    
    
    
    
    
    
    
    
    5Issuance of shares for cash
    
    June 2005
    
    
    
    50,000
    
    
    
    
    
    
    
    3
    
    
    
    
    
    
    
    
    
    
    
    3Issuance of shares for cash
    
    June 2005
    
    
    
    50,000
    
    
    
    
    
    
    
    3
    
    
    
    
    
    
    
    
    
    
    
    3Issuance of shares for cash
    
    June 2005
    
    
    
    343,500
    
    
    
    3
    
    
    
    14
    
    
    
    
    
    
    
    
    
    
    
    17Issuance of shares for cash
    
    June 2005
    
    
    
    83,300
    
    
    
    1
    
    
    
    3
    
    
    
    
    
    
    
    
    
    
    
    4Issuance of shares for cash
    
    June 2005
    
    
    
    100,000
    
    
    
    1
    
    
    
    4
    
    
    
    
    
    
    
    
    
    
    
    5Issuance of shares for cash
    
    July 2005
    
    
    
    144,516
    
    
    
    1
    
    
    
    6
    
    
    
    
    
    
    
    
    
    
    
    7Issuance of shares for cash
    
    July 2005
    
    
    
    144,516
    
    
    
    1
    
    
    
    6
    
    
    
    
    
    
    
    
    
    
    
    7Issuance of shares for cash
    
    July 2005
    
    
    
    144,516
    
    
    
    1
    
    
    
    6
    
    
    
    
    
    
    
    
    
    
    
    7Issuance of shares for cash
    
    August 2005
    
    
    
    206,452
    
    
    
    2
    
    
    
    8
    
    
    
    
    
    
    
    
    
    
    
    10Issuance of shares for cash
    
    August 2005
    
    
    
    50,000
    
    
    
    
    
    
    
    2
    
    
    
    
    
    
    
    
    
    
    
    2Issuance of shares for services
    
    September 2005
    
    
    
    500,000
    
    
    
    4
    
    
    
    8
    
    
    
    
    
    
    
    
    
    
    
    12Issuance of shares for services
    
    September 2005
    
    
    
    500,000
    
    
    
    4
    
    
    
    8
    
    
    
    
    
    
    
    
    
    
    
    12Issuance of shares for services
    
    September 2005
    
    
    
    500,000
    
    
    
    4
    
    
    
    8
    
    
    
    
    
    
    
    
    
    
    
    12Issuance of shares for services
    
    September 2005
    
    
    
    300,000
    
    
    
    3
    
    
    
    5
    
    
    
    
    
    
    
    
    
    
    
    8Issuance of shares for services
    
    September 2005
    
    
    
    68,000
    
    
    
    1
    
    
    
    1
    
    
    
    
    
    
    
    
    
    
    
    2Issuance of shares for services
    
    September 2005
    
    
    
    173,200
    
    
    
    1
    
    
    
    3
    
    
    
    
    
    
    
    
    
    
    
    4Issuance of shares for cash
    
    October 2005
    
    
    
    87,459
    
    
    
    1
    
    
    
    2
    
    
    
    
    
    
    
    
    
    
    
    3Issuance of shares for services
    
    October 2005
    
    
    
    185,000
    
    
    
    2
    
    
    
    6
    
    
    
    
    
    
    
    
    
    
    
    8Issuance of shares for cash
    
    October 2005
    
    
    
    174,918
    
    
    
    1
    
    
    
    5
    
    
    
    
    
    
    
    
    
    
    
    6Issuance of shares for cash
    
    October 2005
    
    
    
    116,612
    
    
    
    1
    
    
    
    3
    
    
    
    
    
    
    
    
    
    
    
    4Issuance of shares for cash
    
    November 2005
     
    
    
    116,611
    
    
    
    1
    
    
    
    3
    
    
    
    
    
    
    
    
    
    
    
    4Issuance of shares for cash
    
    November 2005
    
    
    
    390,667
    
    
    
    3
    
    
    
    3
    
    
    
    
    
    
    
    
    
    
    
    6Issuance of shares for services
    
    November 2005
    
    
    
    20,000
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    Issuance of shares for services
    
    November 2005
    
    
    
    20,000
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    Issuance of shares for services
    
    November 2005
    
    
    
    20,000
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    Issuance of shares for services
    
    November 2005
    
    
    
    500,000
    
    
    
    5
    
    
    
    9
    
    
    
    
    
    
    
    
    
    
    
    14Issuance of shares for services
    
    December 2005
    
    
    
    140,000
    
    
    
    2
    
    
    
    2
    
    
    
    
    
    
    
    
    
    
    
    4Issuance of shares for cash
    
    December 2005
    
    
    
    390,667
    
    
    
    3
    
    
    
    3
    
    
    
    
    
    
    
    
    
    
    
    6Issuance of shares for cash
    
    December 2005
    
    
    
    390,666
    
    
    
    3
    
    
    
    3
    
    
    
    
    
    
    
    
    
    
    
    6Issuance of shares for cash
    
    December 2005
    
    
    
    6,000,000
    
    
    
    50
    
    
    
    200
    
    
    
    
    
    
    
    
    
    
    
    250Net loss for the year
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (1,939
    )
    
    
    
    
    
    
    (1,939
    )Translation adjustment
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (98
    )
    
    
    (98
    )Balance at December 31, 2005
    
    
    
    
    
    
    82,670,464
    
    
    
    837
    
    
    
    6,227
    
    
    
    (14,087
    )
    
    
    743
    
    
    
    (6,280
    )
 52




---



##### Table of Contents



AccumulatedOtherDeficit
    
    
    ComprehensiveAccumulated
    
    
    Income  ForeignAdditional
    
    
    During the
    
    
    CurrencyDate of
    
    
    Number of
    
    
    Par
    
    
    Paid-in
    
    
    Development
    
    
    TranslationTransaction
    
    
    Shares
    
    
    Value
    
    
    Capital
    
    
    Stage
    
    
    Adjustment
    
    
    TotalIssuance of shares for services
    
    January 2006
    
    
    
    2,500,000
    
    
    
    21
    
    
    
    31
    
    
    
    
    
    
    
    
    
    
    
    52Issuance of shares for cash
    
    January 2006
    
    
    
    4,000,000
    
    
    
    33
    
    
    
    132
    
    
    
    
    
    
    
    
    
    
    
    165Issuance of shares for services
    
    January 2006
    
    
    
    100,000
    
    
    
    1
    
    
    
    2
    
    
    
    
    
    
    
    
    
    
    
    3Issuance of shares for cash
    
    March 2006
    
    
    
    1,500,000
    
    
    
    12
    
    
    
    38
    
    
    
    
    
    
    
    
    
    
    
    50Issuance of shares for cash
    
    March 2006
    
    
    
    2,500,000
    
    
    
    21
    
    
    
    62
    
    
    
    
    
    
    
    
    
    
    
    83Issuance of shares for cash
    
    March 2006
    
    
    
    250,000
    
    
    
    2
    
    
    
    6
    
    
    
    
    
    
    
    
    
    
    
    8Issuance of shares for cash
    
    March 2006
    
    
    
    1,500,000
    
    
    
    12
    
    
    
    38
    
    
    
    
    
    
    
    
    
    
    
    50Issuance of shares for services
    
    April 2006
    
    
    
    100,000
    
    
    
    1
    
    
    
    4
    
    
    
    
    
    
    
    
    
    
    
    5Issuance of shares for cash
    
    May 2006
    
    
    
    300,000
    
    
    
    2
    
    
    
    3
    
    
    
    
    
    
    
    
    
    
    
    5Issuance of shares for cash
    
    May 2006
    
    
    
    300,000
    
    
    
    3
    
    
    
    7
    
    
    
    
    
    
    
    
    
    
    
    10Issuance of shares for cash
    
    May 2006
    
    
    
    2,350,000
    
    
    
    18
    
    
    
    82
    
    
    
    
    
    
    
    
    
    
    
    100Debt Conversion  non cash
    
    May 2006
    
    
    
    1,000,000
    
    
    
    8
    
    
    
    31
    
    
    
    
    
    
    
    
    
    
    
    39Issuance of shares for cash
    
    June 2006
    
    
    
    2,600,000
    
    
    
    20
    
    
    
    80
    
    
    
    
    
    
    
    
    
    
    
    100Debt Conversion  non cash
    
    July 2006
    
    
    
    1,000,000
    
    
    
    8
    
    
    
    72
    
    
    
    
    
    
    
    
    
    
    
    80Debt Conversion  non cash
    
    July 2006
    
    
    
    1,000,000
    
    
    
    8
    
    
    
    72
    
    
    
    
    
    
    
    
    
    
    
    80Debt Conversion  non cash
    
    July 2006
    
    
    
    1,000,000
    
    
    
    8
    
    
    
    72
    
    
    
    
    
    
    
    
    
    
    
    80Debt Conversion  non cash
    
    July 2006
    
    
    
    500,000
    
    
    
    4
    
    
    
    36
    
    
    
    
    
    
    
    
    
    
    
    40Issuance of shares for services
    
    November 2006
    
    
    
    300,000
    
    
    
    2
    
    
    
    4
    
    
    
    
    
    
    
    
    
    
    
    6Issuance of shares for cash
    
    November 2006
    
    
    
    1,300,000
    
    
    
    10
    
    
    
    90
    
    
    
    
    
    
    
    
    
    
    
    100Issuance of shares for cash
    
    November 2006
    
    
    
    1,280,000
    
    
    
    10
    
    
    
    90
    
    
    
    
    
    
    
    
    
    
    
    100Issuance of shares for cash
    

    December 2006
    
    
    
    1,320,000
    
    
    
    10
    
    
    
    90
    
    
    
    
    
    
    
    
    
    
    
    100Issuance of shares for cash
    
    December 2006
    
    
    
    1,320,000
    
    
    
    10
    
    
    
    90
    
    
    
    
    
    
    
    
    
    
    
    100Issuance of shares for cash
    
    December 2006
    
    
    
    330,000
    
    
    
    3
    
    
    
    22
    
    
    
    
    
    
    
    
    
    
    
    25Net loss for the year
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (1,585
    )
    
    
    
    
    
    
    (1,585
    )Translation adjustment
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    4
    
    
    
    4Balance at December 31, 2006
    
    
    
    
    
    
    111,020,464
    
    
    
    1,064
    
    
    
    7,381
    
    
    
    (15,672
    )
    
    
    747
    
    
    
    (6,480
    )
 53




---



##### Table of Contents



AccumulatedOtherDeficit
    
    
    ComprehensiveAccumulated
    
    
    Income  ForeignAdditional
    
    
    During the
    
    
    CurrencyDate of
    
    
    Number of
    
    
    Par
    
    
    Paid-in
    
    
    Development
    
    
    TranslationTransaction
    
    
    Shares
    
    
    Value
    
    
    Capital
    
    
    Stage
    
    
    Adjustment
    
    
    TotalIssuance of shares for cash
    
    January 2007
    
    
    
    650,000
    
    
    
    5
    
    
    
    45
    
    
    
    
    
    
    
    
    
    
    
    50Issuance of shares for services
    
    January 2007
    
    
    
    300,000
    
    
    
    2
    
    
    
    6
    
    
    
    
    
    
    
    
    
    
    
    8Issuance of shares for services
    
    January 2007
    
    
    
    200,000
    
    
    
    2
    
    
    
    4
    
    
    
    
    
    
    
    
    
    
    
    6Issuance of shares for services
    
    January 2007
    
    
    
    250,000
    
    
    
    2
    
    
    
    5
    
    
    
    
    
    
    
    
    
    
    
    7Issuance of shares for services
    
    February 2007
    
    
    
    250,000
    
    
    
    2
    
    
    
    5
    
    
    
    
    
    
    
    
    
    
    
    7Issuance of shares for cash
    
    February 2007
    
    
    
    1,420,000
    
    
    
    11
    
    
    
    99
    
    
    
    
    
    
    
    
    
    
    
    110Issuance of shares for cash
    
    February 2007
    
    
    
    325,000
    
    
    
    2
    
    
    
    22
    
    
    
    
    
    
    
    
    
    
    
    24Issuance of shares for cash
    
    March 2007
    
    
    
    650,000
    
    
    
    5
    
    
    
    45
    
    
    
    
    
    
    
    
    
    
    
    50Issuance of shares for cash
    
    March 2007
    
    
    
    8,712,000
    
    
    
    115
    
    
    
    875
    
    
    
    
    
    
    
    
    
    
    
    990Debt Conversion  non cash
    
    March 2007
    
    
    
    12,500,000
    
    
    
    94
    
    
    
    2,505
    
    
    
    
    
    
    
    
    
    
    
    2,599Issuance of shares for services
    
    April 2007
    
    
    
    100,000
    
    
    
    1
    
    
    
    13
    
    
    
    
    
    
    
    
    
    
    
    14Issuance of shares for services
    
    April 2007
    
    
    
    200,000
    
    
    
    1
    
    
    
    25
    
    
    
    
    
    
    
    
    
    
    
    26Issuance of shares for services
    
    April 2007
    
    
    
    1,000,000
    
    
    
    7
    
    
    
    67
    
    
    
    
    
    
    
    
    
    
    
    74Issuance of shares for cash
    
    May 2007
    
    
    
    1,000,000
    
    
    
    7
    
    
    
    140
    
    
    
    
    
    
    
    
    
    
    
    147Issuance of shares for cash
    
    May 2007
    
    
    
    750,000
    
    
    
    6
    
    
    
    105
    
    
    
    
    
    
    
    
    
    
    
    111Debt Cancellation  non cash
    
    May 2007
    
    
    
    
    
    
    
    
    
    
    
    242
    
    
    
    
    
    
    
    
    
    
    
    242Debt Conversion  non cash
    
    June 2007
    
    
    
    9,469,000
    
    
    
    70
    
    
    
    891
    
    
    
    
    
    
    
    
    
    
    
    961Issuance of shares for cash
    
    June 2007
    
    
    
    5,393,000
    
    
    
    40
    
    
    
    760
    
    
    
    
    
    
    
    
    
    
    
    800Issuance of shares for services
    
    June 2007
    
    
    
    261,250
    
    
    
    2
    
    
    
    25
    
    
    
    
    
    
    
    
    
    
    
    27Issuance of shares for services
    
    June 2007
    
    
    
    261,250
    
    
    
    2
    
    
    
    25
    
    
    
    
    
    
    
    
    
    
    
    27Issuance of shares for officer
compensation
    
    June 2007
    
    
    
    2,500,000
    
    
    
    19
    
    
    
    318
    
    
    
    
    
    
    
    
    
    
    
    337Issuance of shares for officer
compensation
    
    June 2007
    
    
    
    2,500,000
    
    
    
    19
    
    
    
    318
    
    
    
    
    
    
    
    
    
    
    
    337Issuance of shares for officer
compensation
    
    June 2007
    
    
    
    4,000,000
    
    
    
    30
    
    
    
    508
    
    
    
    
    
    
    
    
    
    
    
    538Issuance of shares for officer
compensation
    
    June 2007
    
    
    
    1,000,000
    
    
    
    7
    
    
    
    127
    
    
    
    
    
    
    
    
    
    
    
    134Issuance of shares for officer
compensation
    
    June 2007
    
    
    
    6,000,000
    
    
    
    45
    
    
    
    762
    
    
    
    
    
    
    
    
    
    
    
    807Issuance of shares for services
    
    June 2007
    
    
    
    135,000
    
    
    
    1
    
    
    
    12
    
    
    
    
    
    
    
    
    
    
    
    13Issuance of shares for cash
    
    June 2007
    
    
    
    2,250,000
    
    
    
    17
    
    
    
    12
    
    
    
    
    
    
    
    
    
    
    
    29Issuance of shares for cash
    
    July 2007
    
    
    
    5,550,000
    
    
    
    42
    
    
    
    1,208
    
    
    
    
    
    
    
    
    
    
    
    1,250Issuance of shares for cash
    
    August 2007
    
    
    
    933,333
    
    
    
    7
    
    
    
    193
    
    
    
    
    
    
    
    
    
    
    
    200Issuance of shares for services
    
    August 2007
    
    
    
    1,000,000
    
    
    
    7
    
    
    
    66
    
    
    
    
    
    
    
    
    
    
    
    73Issuance of shares for services
    
    August 2007
    
    
    
    1,000,000
    
    
    
    7
    
    
    
    66
    
    
    
    
    
    
    
    
    
    
    
    73Issuance of shares for services
    
    August 2007
    
    
    
    100,000
    
    
    
    1
    
    
    
    7
    
    
    
    
    
    
    
    
    
    
    
    8Issuance of shares for services
    
    September 2007
    
    
    
    300,000
    
    
    
    2
    
    
    
    21
    
    
    
    
    
    
    
    
    
    
    
    23Issuance of shares for cash
    
    September 2007
    
    
    
    1,666,667
    
    
    
    12
    
    
    
    344
    
    
    
    
    
    
    
    
    
    
    
    356Cancellation of shares for
collateral
    
    September 2007
    
    
    
    -2,000,000
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    Issuance of shares for cash
    
    October 2007
    
    
    
    2,350,000
    
    
    
    17
    
    
    
    483
    
    
    
    
    
    
    
    
    
    
    
    500Issuance of shares for cash
    
    November 2007
    
    
    
    2,966,666
    
    
    
    21
    
    
    
    623
    
    
    
    
    
    
    
    
    
    
    
    644Issuance of shares for services
    
    December 2007
    
    
    
    500,000
    
    
    
    3
    
    
    
    48
    
    
    
    
    
    
    
    
    
    
    
    51Net loss for the year
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (9,294
    )
    
    
    
    
    
    
    (9,294
    )Translation adjustment
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (75
    )
    
    
    (75
    )Balance at December 31, 2007
    
    
    
    
    
    
    187,463,630
    
    
    
    1,697
    
    
    
    18,401
    
    
    
    (24,966
    )
    
    
    672
    
    
    
    (4,196
    )
 54




---



##### Table of Contents



AccumulatedOtherDeficit
    
    
    ComprehensiveAccumulated
    
    
    Income  ForeignAdditional
    
    
    During the
    
    
    CurrencyDate of
    
    
    Number of
    
    
    Par
    
    
    Paid-in
    
    
    Development
    
    
    TranslationTransaction
    
    
    Shares
    
    
    Value
    
    
    Capital
    
    
    Stage
    
    
    Adjustment
    
    
    TotalIssuance of shares for services
    
    January 2008
    
    
    
    800,000
    
    
    
    6
    
    
    
    79
    
    
    
    
    
    
    
    
    
    
    
    85Issuance of shares for services
    
    January 2008
    
    
    
    200,000
    
    
    
    1
    
    
    
    20
    
    
    
    
    
    
    
    
    
    
    
    21Issuance of shares for cash
    
    February 2008
    
    
    
    1,000,000
    
    
    
    7
    
    
    
    326
    
    
    
    
    
    
    
    
    
    
    
    333Issuance of shares for services
    
    March 2008
    
    
    
    500,000
    
    
    
    3
    
    
    
    73
    
    
    
    
    
    
    
    
    
    
    
    76Issuance of shares for services
    
    March 2008
    
    
    
    500,000
    
    
    
    3
    
    
    
    73
    
    
    
    
    
    
    
    
    
    
    
    76Issuance of shares for cash
    
    June 2008
    
    
    
    300,000
    
    
    
    2
    
    
    
    94
    
    
    
    
    
    
    
    
    
    
    
    96Issuance of shares for cash
    
    June 2008
    
    
    
    1,300,000
    
    
    
    8
    
    
    
    492
    
    
    
    
    
    
    
    
    
    
    
    500Issuance of shares for services
    
    July 2008
    
    
    
    2,000,000
    
    
    
    13
    
    
    
    239
    
    
    
    
    
    
    
    
    
    
    
    252Issuance of shares for services
    
    August 2008
    
    
    
    250,000
    
    
    
    2
    
    
    
    39
    
    
    
    
    
    
    
    
    
    
    
    41Issuance of shares for cash
    
    December 2008
    
    
    
    1,000,000
    
    
    
    7
    
    
    
    319
    
    
    
    
    
    
    
    
    
    
    
    326Net loss for the period
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (6,938
    )
    
    
    
    
    
    
    (6,938
    )Translation adjustment
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    13
    
    
    
    13Balance at December 31, 2008
    
    
    
    
    
    
    195,313,630
    
    
    
    1,749
    
    
    
    20,155
    
    
    
    (31,904
    )
    
    
    685
    
    
    
    (9,315
    )Issuance of shares for services
    
    March 2009
    
    
    
    250,000
    
    
    
    2
    
    
    
    36
    
    
    
    
    
    
    
    
    
    
    
    38Issuance of stock options for
acquisition
    
    April 2009
    
    
    
    
    
    
    
    
    
    
    
    601
    
    
    
    
    
    
    
    
    
    
    
    601Issuance of shares for services
    
    May 2009
    
    
    
    250,000
    
    
    
    1
    
    
    
    27
    
    
    
    
    
    
    
    
    
    
    
    28Issuance of shares for services
    
    September 2009
    
    
    
    250,000
    
    
    
    2
    
    
    
    21
    
    
    
    
    
    
    
    
    
    
    
    23Net loss for the period
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (10,186
    )
    
    
    
    
    
    
    (10,186
    )Translation adjustment
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (4
    )
    
    
    (4
    )Balance at December 31, 2009
    
    
    
    
    
    
    196,063,630
    
    
    E
    1,754
    
    
    E
    20,840
    
    
    E
    (42,090
    )
    
    E
    681
    
    
    E
    (18,815
    )
  55




---



##### Table of Contents



TotalAccumulatedDuringDevelopmentStage(May 2, 1990 toDecember 31,2009
    
    
    2008
    
    
    2009)Cash Flows from Operating ActivitiesNet loss
    
    E
    (10,186
    )
    
    E
    (6,938
    )
    
    E
    (42,090
    )Adjustments to reconcile net loss to net cash
used in operating activities
Change in the fair value of acquisition-related
contingent consideration
    
    
    (1,614
    )
    
    
    
    
    
    
    (1,614
    )Depreciation and amortization
    
    
    226
    
    
    
    17
    
    
    
    756Goodwill impairment
    
    
    
    
    
    
    
    
    
    
    209Fees paid in warrants
    
    
    
    
    
    
    
    
    
    
    223Gain on extinguishment of debt
    
    
    
    
    
    
    
    
    
    
    (774
    )Services and fees paid in common stock
    
    
    89
    
    
    
    551
    
    
    
    5,224Amortization of debt discount
    
    
    
    
    
    
    
    
    
    
    210Changes in operating assets and liabilities,
net of effects from reverse purchase
Receivables
    
    
    1
    
    
    
    57
    
    
    
    25Accounts payable
    
    
    374
    
    
    
    (1,316
    )
    
    
    2,121Taxes and social costs payable
    
    
    16
    
    
    
    21
    
    
    
    41Other
    
    
    48
    
    
    
    (110
    )
    
    
    11Net cash used in operating activities
    
    
    (11,046
    )
    
    
    (7,718
    )
    
    
    (35,658
    )Cash Flows from Investing ActivitiesPatents and other
    
    
    
    
    
    
    
    
    
    
    (393
    )Purchase of property and equipment
    
    
    (140
    )
    
    
    (83
    )
    
    
    (223
    )Acquisition of subsidiary, net of cash acquired of E58
    
    
    (4,942
    )
    
    
    
    
    
    
    (4,942
    )Short-term investments
    
    
    
    
    
    
    60
    
    
    
    Cash acquired in reverse purchase
    
    
    
    
    
    
    
    
    
    
    13Net cash used in investing activities
    
    
    (5,082
    )
    
    
    (23
    )
    
    
    (5,545
    )Cash Flows from Financing ActivitiesProceeds from the issuance of
common stock and warrants
    
    
    
    
    
    
    1,255
    
    
    
    11,630Borrowings from shareholders
    
    
    
    
    
    
    
    
    
    
    972Increase in notes payable and other
short-term advances
    
    
    18,582
    
    
    
    6,823
    
    
    
    32,499Decrease in notes payable and other
short-term advances
    
    
    
    
    
    
    
    
    
    
    (1,490
    )Loan fees
    
    
    
    
    
    
    
    
    
    
    (130
    )Net cash provided by financing activities
    
    
    18,582
    
    
    
    8,078
    
    
    
    43,481Effect of exchange rate changes on cash
    
    
    (4
    )
    
    
    13
    
    
    
    681Net increase in cash
    
    
    2,450
    
    
    
    350
    
    
    
    2,959Cash, beginning of period
    
    
    509
    
    
    
    159
    
    
    
    Cash, end of period
    
    E
    2,959
    
    
    E
    509
    
    
    E
    2,959
  56




---



##### Table of Contents



57




---



##### Table of Contents



st
 58




---



##### Table of Contents



59




---



##### Table of Contents



Level 1-
    
    Quoted prices in active markets for identical assets or liabilities.Level 2-
    
    Inputs other than Level 1 that are observable, either directly or
indirectly, such as quoted prices for similar assets or liabilities; quoted
prices in markets that are not active; or other inputs that are observable or
can be corroborated by observable market data for substantially the full term of
the assets or liabilities.Level 3-
    
    Unobservable inputs that are supported by little or no market activity and
that are significant to the fair value of the assets or liabilities.
      60




---



##### Table of Contents



2009
    
    
    2008Receivable officer
    
    
    6
    
    
    
    8Receivable other
    
    
    200
    
    
    
    144206
    
    
    
    152Allowance for doubtful accounts
    
    
    (161
    )
    
    
    (138
    )E
    45
    
    
    E
    14
     61




---



##### Table of Contents



FixedEUR/USDDura-
    
    
    Inter-
    
    
    Conversion
    
    
    Rate forPrincipal
    
    
    1st-Issue
    
    
    tion
    
    
    est
    
    
    Price
    
    
    ConversionLender
    
    Amount
    
    
    Date
    
    
    (Note)
    
    
    Rate
    
    
    (stated)
    
    
    PriceEardley Holding A.G. (1)
    
    E
    133
    
    
    
    06/23/2006
    
    
    
    (2
    )
    
    10% pa
    
    US$
    0.10
    
    
    
    N/AAnglo Irish Bank S.A. (3)
    
    E
    500
    
    
    
    10/21/2007
    
    
    
    (2
    )
    
    10% pa
    
    US$
    0.50
    
    
    
    1.4090Round Enterprises Ltd.
    
    E
    1,500
    
    
    
    12/10/2007
    
    
    
    (2
    )
    
    10% pa
    
    US$
    0.50
    
    
    
    1.4429Round Enterprises Ltd.
    
    E
    1,500
    
    
    
    01/22/2008
    
    
    
    (2
    )
    
    10% pa
    
    US$
    0.50
    
    
    
    1.4629Round Enterprises Ltd.
    
    E
    2,000
    
    
    
    04/25/2008
    
    
    
    (2
    )
    
    10% pa
    
    US$
    0.50
    
    
    
    1.5889Round Enterprises Ltd.
    
    E
    1,500
    
    
    
    06/30/2008
    
    
    
    (2
    )
    
    10% pa
    
    US$
    0.50
    
    
    
    1.5380Round Enterprises Ltd.
    
    E
    1,200
    
    
    
    11/18/2008
    
    
    
    (2
    )
    
    10% pa
    
    US$
    0.50
    
    
    
    1.2650Round Enterprises Ltd.
    
    E
    1,500
    
    
    
    02/09/2009
    
    
    
    (2
    )
    
    10% pa
    
    US$
    0.50
    
    
    
    1.2940Round Enterprises Ltd.
    
    E
    5,500
    
    
    
    06/15/2009
    
    
    
    (2
    )
    
    10% pa
    
    US$
    0.80
    
    
    
    1.4045Eardley Holding A.G.
    
    E
    100
    
    
    
    06/15/2009
    
    
    
    (2
    )
    
    10% pa
    
    US$
    0.80
    
    
    
    1.4300Von Meyenburg
    
    E
    200
    
    
    
    08/03/2009
    
    
    
    (2
    )
    
    10% pa
    
    US$
    0.80
    
    
    
    1.4400Round Enterprises Ltd.
    
    E
    2,000
    
    
    
    10/13/2009
    
    
    
    (2
    )
    
    5% pa
    
    US$
    0.25
    
    
    
    1.4854Round Enterprises Ltd.
    
    E
    2,200
    
    
    
    12/18/2009
    
    
    
    (2
    )
    
    5% pa
    
    US$
    0.25
    
    
    
    1.4338Total long termPrincipal Amounts
    
    E
    19,833Accrued Interest
    
    E
    1,889Total long term
Convertible Notes
to Related Parties
    
    E
    21,722Round Enterprises Ltd.
    
    E
    4,000
    
    
    
    04/03/2009
    
    
    
    (4
    )
    
    10% pa
    
    US$
    0.80
    
    
    
    1.3486Eardley Holding A.G.
    
    E
    1,000
    
    
    
    04/03/2009
    
    
    
    (4
    )
    
    10% pa
    
    NoneTotal short termPrincipal Amounts
    
    E
    5,000Accrued Interest
    
    E
    740Total short term
Convertible Notes
to Related Parties
    
    E
    5,740Total Convertible
Notes to Related
Parties
    
    E
    27,462Norwood Secured Loan
    
    E
    2,500
    
    
    
    04/03/2009
    
    
    
    (5
    )
    
    5% pa
    
    US$
    0.80
    
    
    
    1.2812Total Principal Amount
    
    E
    2,500Accrued Interest
    
    E
    93Total Convertible Note
Payable  other
    
    E
    2,593Norwood contingent
liability
    
    E
    1,936
    
    
    
    
    
    
    
    (6
    )TOTAL NOTES,LOANS AND
CONTINGENT LIABILITY
    
    E
    31,991
 
 (1)
    
    Private investment company of Dr. Thomas Staehelin, member of the Board of Directors and
of the Audit Committee of the Company. Face value is stated in U.S. dollars at $190,000.(2)
    
    The earlier of: (i) The date that the Company has sufficient revenues to repay, or (ii) upon
an event of default. The loan is secured against IP assets of Mymetics Corporation.(3)
    
    Renamed Hyposwiss Private Bank Genève S.A. and acting on behalf of Round Enterprises Ltd.
which is a major shareholder.(4)
    
    The earlier of (i) June 30, 2010 or (ii) upon an event of default. The loan is secured against
two third of the IP assets of Bestewil Holding BV and convertible for shares.(5)
    
    Under the terms of the acquisition of Bestewil BV, as part of the consideration, the Company
issued to Norwood Immunology Limited (NIL) a convertible redeemable note (the Note) in the
principal amount of E2,500 with maturity 36 months after the closing date and bearing interest at 5% per annum. The note is secured against one third of Bestewil shares.(6)
    
    Under the terms of the acquisition of Bestewil BV, as part of the consideration, the Company
is committed to make further payments to NIL in the event that certain stated milestones for the
development of vaccines are achieved. These have been considered on a risk probability basis. 62




---



##### Table of Contents



2009
    
    
    2008U.S. Federal statutory rates on loss from operations
    
    E
    (3,466
    )
    
    E
    (2,353
    )Effect of foreign statutory rate differences
    
    
    185
    
    
    
    Effect of exchange rate changes
    
    
    36
    
    
    
    (454
    )Permanent differences
    
    
    (549
    )
    
    
    Increase in valuation allowance
    
    
    3,781
    
    
    
    2,925Other
    
    
    3
    
    
    
    (100
    )Income tax provision (benefit)
    
    E
    (10
    )
    
    E
    18
  2009
    
    
    2008Licenses capitalized for United States tax purposes
    
    E
    1,279
    
    
    E
    1,385License contract basis difference
    
    
    (867
    )
    
    
    IPR&D basis difference
    
    
    (770
    )
    
    
    Other
    
    
    54
    
    
    
    Net operating loss carry forwardsUnited States
    
    
    11,818
    
    
    
    8,722Switzerland
    
    
    459
    
    
    
    The Netherlands
    
    
    228
    
    
    
    Luxembourg
    
    
    174
    
    
    
    17312,375
    
    
    
    10,280Less valuation allowance for deferred tax asset
    
    
    (12,375
    )
    
    
    (10,280
    )Net deferred tax asset
    
    E
    
    
    
    E
    
 63




---



##### Table of Contents



United States
    
    
    Luxembourg
    
    
    Switzerland
    
    
    The Netherlands2010
    
    E
    
    
    
    E
    
    
    
    E
    
    
    
    E
    2011
    
    
    552
    
    
    
    
    
    
    
    
    
    
    
    2012
    
    
    1,011
    
    
    
    
    
    
    
    
    
    
    
    2013
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    2014
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    2015-2028
    
    
    33,196
    
    
    
    
    
    
    
    1,834
    
    
    
    911Perpetual
    
    
    
    
    
    
    793
    
    
    
    
    
    
    
    E
    34,759
    
    
    E
    793
    
    
    E
    1,834
    
    
    E
    911
    Weighted
    
    Weighted AverageNumber
    
    Average
    
    Remainingof
    
    Exercise
    
    ContractualOptions
    
    Price
    
    Term (Years)Outstanding and exercisable
at December 31, 2007, 2008 and 2009
    
    
    442,500
    
    
    
    U.S. $.97
    
    
    
    3.1Reserved for future grants
at December 31, 2009
    
    
    4,557,500
      64




---



##### Table of Contents



Office Rent Expected
    
    2010
    
    
    2011
    
    
    2012
    
    
    2013
    
    
    2014
    
    
    2015-18NYON
    
    E
    18
    
    
    E
    18
    
    
    E
    4
    
    
    E
    
    
    
    E
    
    
    
    E
    LAUSANNE
    
    E
    120
    
    
    E
    120
    
    
    E
    120
    
    
    E
    120
    
    
    E
    120
    
    
    E
    480LEIDEN
    
    E
    48
    
    
    E
    
    
    
    E
    
    
    
    E
    
    
    
    E
    
    
    
    E
    TOTAL
    
    E
    186
    
    
    E
    138
    
    
    E
    124
    
    
    E
    120
    
    
    E
    120
    
    
    E
    480
    
    
    A payment of up to E2,800 in cash in the event of a license agreement being signed by
April 1, 2011 with a third party to access Bestewil intellectual property and know-how in
the field of Respiratory Syncytial Virus (RSV License);
    
    A payment of up to E3,000 in cash should a third party commence a Phase III clinical
trial by April 1, 2013 for Mymetics Intranasal Influenza Vaccine licensed from Bestewil;
    
    A payment of 50% of Mymetics net royalties received from a Respiratory Syncytial Virus
license (RSV license), payable in cash, maximum amount unlimited; and
    
    A payment in cash, maximum amount unlimited, of 25% of any net amounts received by
Mymetics from a third party Herpes Simplex Virus license (HSV license) based upon Bestewil
intellectual property.
    65




---



##### Table of Contents



As
    
    
    MeasurementInitially
    
    
    Period
    
    
    AsRecorded
    
    
    Adjustments
    
    
    AdjustedCash paid to Norwood
    
    E
    5,000
    
    
    E
    
    
    
    E
    5,000Convertible note payable issued
    
    
    2,500
    
    
    
    
    
    
    
    2,500Equity options issued
    
    
    601
    
    
    
    
    
    
    
    601Contingent consideration:Royalties for Influenza Vaccine
    
    
    
    
    
    
    1,800
    
    
    
    1,800Royalties for RSV
    
    
    700
    
    
    
    729
    
    
    
    1,429Royalties for HSV
    
    
    750
    
    
    
    (429
    )
    
    
    321Total purchase consideration
    
    E
    9,551
    
    
    E
    2,100
    
    
    E
    11,651
   Expected volatility
    
    
    157.60
    %Risk-free interest rate
    
    
    0.65
    %Expected term in years
    
    
    1.5Dividend yield
    
    
    0.00
    %
 66




---



##### Table of Contents



Purchase Price AllocationAssets:Current assets
    
    E
    90License contract (Intranasal Influenza Vaccine)
    
    
    2,694In-process research and development (HSV and RSV)
    
    
    2,266Goodwill
    
    
    6,671Property and equipment
    
    
    98Other non-current assets
    
    
    7Total assets
    
    
    11,826Liabilities:Current liabilities
    
    
    175Total liabilities
    
    E
    175Total purchase consideration
    
    E
    11,651
      YEAR ENDEDDECEMBER 31, 2009Revenue
    
    E
    233Net loss
    
    E
    (10,199
    )
  67




---



##### Table of Contents



Fair Value MeasurementsUsing SignificantUnobservable Inputs(Level 3)Acquisition-relatedContingent ConsiderationLiabilities:Balance at January 1, 2009
    
    E
    Amounts acquired or issued
    
    
    3,550Transfers in and/or (out) of Level 3
    
    
    Change in fair value recorded in earnings
    
    
    (1,614
    )Balance at December 31, 2009
    
    E
    1,936
    December 31, 2009Indefinite-lived intangibles:In process research and development
    
    E
    2,266Definite-lived intangibles:License contract
    
    E
    2,694Less accumulated amortization
    
    
    (144
    )2,550Other intangibles, net
    
    E
    4,816
     68




---



##### Table of Contents



Mymetics CorporationBy:
    /s/ Jacques-François MartinName:
    Jacques-François MartinTitle:
    Chief Executive OfficerDate:
    April 15, 2010 69




---



##### Table of Contents



Signature
    
    Title/s/ Jacques-François Martin
    
    Chief Executive Officer and DirectorJacques-François Martin
    
    (Principal Executive Officer)April 15, 2010/s/ Ernst Luebke
    
    Chief Financial Officer and DirectorErnst Luebke
    
    (Principal Financial and Accounting Officer)April 15, 2010/s/ Sylvain Fleury
    
    Chief Scientific Officer and DirectorSylvain Fleury, Ph.D.April 15, 2010
 70